AER CoverageIndependent Research

Helus Pharma Inc.

Equity Research & Valuation

Ticker: HELP
Exchange: NASDAQ
Country: Canada

Healthcare · Biotechnology

Business Overview

Helus Pharma Inc. is a clinical-stage biotechnology company developing investigational novel serotonergic therapies for psychiatric and neurological conditions. Its lead oral candidate, HLP003, is in Phase 3 development as an adjunctive treatment for major depressive disorder. HLP004 is being developed for generalized anxiety disorder, and HLP005 is a preclinical discovery program.

Sector: Healthcare
Industry: Biotechnology
Coverage Type: Independent Research

Price History

Helus Pharma Inc. Research Archive

Published research will appear here.

AER Insights

Illustrative supervised treatment room with a reclining chair, eye mask and blood-pressure cuff.

Biotechnology & Healthcare

Helus Pharma Redesigns Its Anxiety Study as Pivotal Depression Data Approach

Helus is moving HLP004 into a larger, placebo-controlled monotherapy study while its lead depression drug approaches a Phase 3 readout. The revised anxiety program could establish a clearer efficacy signal, but near-term shareholder value depends more heavily on HLP003 and the cost of completing its development.

Alliance Equity ResearchOctober 22, 20268 min read

Read article

Fundamentals

Market information is supplied by TradingView and may be delayed or unavailable for certain exchanges or instruments. It does not constitute investment advice.